Dendritic cells, inflammation, and breast cancer

Cancer Journal (United States)

Volumn 19, Issue 6, 2013, Pages 511-516

  Palucka, Karolina ^a,b   Coussens, Lisa M ^c   O'Shaughnessy, Joyce ^d  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Th2; Cancer; Dendritic Cells; Immunogenic Cell Death; Inflammation

Indexed keywords

ANTHRACYCLINE; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; MUCIN 1; OX40 LIGAND; OXALIPLATIN; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 4;

BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; EPITHELIUM TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; MONOCYTE; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TH2 CELL;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; DENDRITIC CELLS; FEMALE; HUMANS; INFLAMMATION;

EID: 84889048897     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000007     Document Type: Review

References (86)

1. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828-4836.
2. Lizee G, Overwijk WW, Radvanyi L, et al. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2012;64:71-90.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
4. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183:2533-2540.
5. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
6. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239-245.
7. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.
8. DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409-418.
9. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-2493.
10. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785.
11. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
12. Crown J, O'Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol. 2012;23(suppl 6):vi56Yvi65.
13. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14: 8010-8018.
14. Kristensen VN, Vaske CJ, Ursini-Siegel J, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109:2802-2807.
15. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21: 309-322.
16. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998;4:1321-1324.
17. Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occurring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res. 2000;60:2136-2139.
18. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704-2715.
19. Park KH, Gad E, Goodell V, et al. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 2008;68:8400-8409.
20. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001;107:477-484.
21. Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol. 2001;28(6 suppl 18):12-20.
22. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
23. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
24. Mantovani A, Romero P, Palucka AK, et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008; 371:771-783.
25. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet Science. 2013;339:286-291.
26. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57-63.
27. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217.
28. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437-3444.
29. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-426.
30. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
31. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2011;30:1-22.
32. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
33. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975-1028.
34. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
35. Helft J, Ginhoux F, Bogunovic M, et al. Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunol Rev. 2010;234:55-75.
36. Segura E, Touzot M, Bohineust A, et al. Human inflammatory dendritic cells induce TH17 cell differentiation. Immunity. 2013;38:336-348.
37. Ueno H, Schmitt N, Klechevsky E, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev. 2010;234:199-212.
38. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferonYproducing cells in human blood. Science. 1999;284: 1835-1837.
39. Di Pucchio T, Chatterjee B, Smed-Sorensen A, et al. Direct proteasomeindependent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol. 2008;9:551-557.
40. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275-306.
41. Lauterbach H, Bathke B, Gilles S, et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med. 2010;207:2703-2717.
42. Crozat K, Guiton R, Contreras V, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207:1283-1292.
43. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247-1260.
44. Bachem A, Guttler S, Hartung E, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010;207:1273-1281.
45. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207:1261-1271.
46. Mittag D, Proietto AI, Loudovaris T, et al. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol. 2011;186:6207-6217.
47. Haniffa M, Shin A, Bigley V, et al. Human tissues contain CD141(hi) cross-presenting dendritic cells with functional homology to mouse CD103(+) nonlymphoid dendritic cells. Immunity. 2012;37:60-73.
48. Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008;29:497-510.
49. Klechevsky E, Flamar AL, Cao Y, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood. 2010;116:1685-1697.
50. Yu CI, Becker C, Wang Y, et al. Human CD1c(+) dendritic cells drive the differentiation of CD103(+) CD8(+) mucosal effector T cells via the cytokine TGF-beta. Immunity. 2013;38:818-830.
51. Le Floc'h A, Jalil A, Vergnon I, et al. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med. 2007;204:559-570.
52. Sandoval F, Terme M, Nizard M, et al. Mucosal imprinting of vaccineinduced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med. 2013;5:172ra20.
53. Mullins DW, Sheasley SL, Ream RM, et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med. 2003;198:1023-1034.
54. Sheasley-O'Neill SL, Brinkman CC, Ferguson AR, et al. Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. J Immunol. 2007; 178:1512-1522.
55. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of guthoming T cells by Peyer's patch dendritic cells. Nature. 2003;424: 88-93.
56. Joffre OP, Segura E, Savina A, et al. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12:557-569.
57. Bluestone JA, Mackay CR, O'Shea JJ, et al. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009;9:811-816.
58. Tanchot C, Terme M, Pere H, et al. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 2012;6:147-157.
59. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cellYdependent mechanism of cancer immunoediting. Nature. 2012;482:400-404.
60. Dong C. TH17 cells in development: An updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8:337-348.
61. Wei S, Zhao E, Kryczek I, et al. TH17 cells have stem cell-like features and promote long-term immunity. Oncoimmunology. 2012;1:516-519.
62. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13Ysecreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007;204:1037-1047.
63. Liu YJ, Soumelis V,Watanabe N, et al. TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219.
64. Pedroza-Gonzalez A, Xu K,Wu TC, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med. 2011;208:479-490.
65. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91-102.
66. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of antitumor immunity and tumor growth. Cancer Immunol Immunother. 2004;53:79-85.
67. Geissmann F, Gordon S, Hume DA, et al. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol. 2010;10:453-460.
68. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585-600.
69. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev. 2010;29:309-316.
70. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.
71. Zhang WJ, Li BH, Yang XZ, et al. IL-4Yinduced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 2008; 42:39-47.
72. Teschendorff AE, Gomez S, Arenas A, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer. 2010;10:604.
73. Denardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54-67.
74. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469-478.
75. Kido M, Tanaka J, Aoki N, et al. Helicobacter pylori promotes the production of thymic stromal lymphopoietin by gastric epithelial cells and induces dendritic cell-mediated inflammatory TH2 responses. Infect Immun. 2010;78:108-114.
76. Chomarat P, Banchereau J, Davoust J, et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1:510-514.
77. Chomarat P, Dantin C, Bennett L, et al. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol. 2003;171: 2262-2269.
78. Hiltbold EM, Vlad AM, Ciborowski P, et al. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol. 2000;165:3730-3741.
79. Cao W, Bover L, Cho M, et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med. 2009;206:1603-1614.
80. Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989-2003.
81. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208:2005-2016.
82. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004; 10:7466-7474.
83. Le Mercier I, Poujol D, Sanlaville A, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 2013;73:4629-4640.
84. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
85. Yamazaki T, Hannani D, Poirier-Colame V, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2013:1-10.
86. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4Ydependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.